Preclinical Evaluation of Di-Sodium Alpha Ketoglutarate against Isoniazid-Rifampicin Induced Hepatotoxicity

This is the authors' abstract. We don't add key points for this paper.

The combination of Isoniazid (INH) and Rifampicin (RIF) is extensively used for the treatment of tuberculosis, but drug induced hepatotoxicity remains the major clinical challenge during treatment. The hepatoprotective role of AKG (Di-sodium Alpha ketoglutarate) is assessed on experimental animal study model. Male Sprague Dawley rats were divided into three groups of 6 animals each. Group I, (Vehicle control): given distilled water only, Group II (INH-RIF): Isoniazid and Rifampicin (50 mg/kg, orally) for 4 weeks, Group III, Treatment group: was given INH-RIF as in group II followed by AKG treatment at a dose of 2gm/kg, orally for 4 weeks. At the end of the experiment animals were sacrificed, blood samples were collected and biochemical and antioxidant assay were performed. Serum biochemical analysis showed elevated ALT, AST levels following INH and RIF exposure which significantly improved with AKG treatment. Antioxidants parameters were correlative to biochemical and histopathological findings. So from the present study it is concluded that AKG protects against INH and RIF induced hepatic injury.